Clinical trial
Repeat-Dose Study of Bavituximab in Patients With Chronic Hepatitis C
NCT00343525 · Peregrine Pharmaceuticals, Industry · Completed
Key facts
| NCT number | NCT00343525 |
|---|---|
| Title | Repeat-Dose Study of Bavituximab in Patients With Chronic Hepatitis C |
| Official title | A Phase Ib Open-Label, Escalating Repeat-Dose Trial of Bavituximab (Chimeric Anti-Phosphatidylserine Monoclonal Antibody) in Patients With Chronic Hepatitis C |
| Lead sponsor | Peregrine Pharmaceuticals, Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Hepatitis C |
| Intervention type | Drug |
| Interventions | bavituximab |
| Enrollment | 24 |
| Start date | May 1, 2006 |
| Primary completion | Jan 1, 2007 |
| First posted | Jun 23, 2006 |
| Last update posted | May 7, 2008 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: